A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 249 participants.

Also called NCT05450601

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 249 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05450601
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05450601. Randomized; double masking; primary purpose treatment. Start 2022-09-01 (actual); primary completion 2023-12-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients
Condition
Hypertension
Intervention (Drug)
HCP2102-1
Intervention (Drug)
HPP2104-1
Intervention (Drug)
HCP2102-2
Intervention (Drug)
HPP2104-2
Intervention (Drug)
RLD2106-1
Intervention (Drug)
HPP2103-1
Intervention (Drug)
RLD2106-2
Intervention (Drug)
HPP2103-2
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct05450601
Content hash
dfa596838693cc3caf556f09748cb3e61217587186a0884bd5b8ae37e9ca923e